TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that James Lanthier, CEO…


Previous articleBraxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients
Next articleBright Minds Biosciences Announces Closing of $4 Million Unit Offering